Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Cancer Res. 2015 Feb 24;75(7):1399–1412. doi: 10.1158/0008-5472.CAN-14-2785

Figure 6. PDK1 and PI3K/mTOR inhibitors synergize to suppress melanoma cell growth.

Figure 6

(A) Western blot analysis of the indicated proteins in YUMM1.9 and SBM-A2 cells treated for 24 h with 0.1, 1, or 5 μM of GSK2334470 (PDK1i) in the presence or absence of 1 or 3 μM of the dual PI3K/mTOR inhibitor BKM120. (B) Western blot analysis of the indicated proteins in the human melanoma cell lines UACC903 and Mel501 treated with 0.1, 1, or 5 μM of GSK2334470 (PDK1i) in the presence or absence of 1 or 3 μM of BKM120. (C) Growth of YUMM1.5 spheroids treated with the indicated concentrations of GSK2334470 (PDK1i) and BKM120 alone or in combination. Relative areas were calculated as described for Figure 2. Values are the mean ± SEM of ≥6 spheroids per group.